The Malignant Neoplasms drugs in development market research report provides comprehensive information on the therapeutics under development for Malignant Neoplasms, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Malignant Neoplasms. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Malignant Neoplasms - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Malignant Neoplasms and features dormant and discontinued products.

GlobalData tracks 31 drugs in development for Malignant Neoplasms by 27 companies/universities/institutes. The top development phase for Malignant Neoplasms is preclinical with 13 drugs in that stage. The Malignant Neoplasms pipeline has 25 drugs in development by companies and six by universities/ institutes. Some of the companies in the Malignant Neoplasms pipeline products market are: UCLAs Jonsson Comprehensive Cancer Center, Jiangsu Pacific Meinuoke Bio-Pharmarceutical and Chia Tai Tianqing Pharmaceutical Group.

The key targets in the Malignant Neoplasms pipeline products market include Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Cells Expressing Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B).

The key mechanisms of action in the Malignant Neoplasms pipeline product include Cytotoxic To Cells Expressing Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) with two drugs in Phase II. The Malignant Neoplasms pipeline products include 12 routes of administration with the top ROA being Intravenous and seven key molecule types in the Malignant Neoplasms pipeline products market including Monoclonal Antibody, and Small Molecule.

Malignant Neoplasms overview

A tumor is a mass comprising atypical neoplastic cells, frequently exhibiting pleomorphism and the capability to invade surrounding tissues. Malignant neoplasms possess the characteristic of metastasizing to distant anatomical sites and may recur even after surgical excision. Among the most prevalent types of malignant neoplasms are carcinomas, which arise from epithelial tissues, Hodgkin and non-Hodgkin lymphomas originating in the lymphatic system, leukemias affecting blood and bone marrow, melanomas arising from pigment-producing cells, and sarcomas affecting connective tissues. These diverse malignancies underline the complexity of cancer pathology, with each type requiring specific diagnostic and therapeutic approaches for effective management.

For a complete picture of Malignant Neoplasms’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.